1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Refractory Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2014

Refractory Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, “Refractory Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2014" provides data on the Refractory Chronic Lymphocytic Leukemia (CLL) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Refractory Chronic Lymphocytic Leukemia (CLL). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Refractory Chronic Lymphocytic Leukemia (CLL). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Refractory Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 6
Introduction 7
Refractory Chronic Lymphocytic Leukemia (CLL) 7
Report Guidance 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Refractory Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials 16
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Refractory Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials 19
Clinical Trials by Phase in E7 Countries 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Refractory Chronic Lymphocytic Leukemia (CLL) 25
Subjects Recruited Over a Period of Time 27
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials 30
Prominent Drugs 32
Latest Clinical Trials News on Refractory Chronic Lymphocytic Leukemia (CLL) 33
Nov 25, 2013: TG Therapeutics Initiates First Combination Clinical Trial of TG-1101 and TGR-1202 in Patients With Relapsed and/or Refractory CLL and NHL 33
Oct 07, 2013: MorphoSys and Xencor Provide Update on Phase 1/2a Trial in CLL/SLL for MOR208 33
Jun 01, 2009: Trubion Announces Positive Data From A Phase I / II Study Of TRU-016 For The Treatment Of Chronic Lymphocytic Leukemia (CLL) 34
Clinical Trial Profiles 36
Clinical Trial Overview of Top Companies 36
F. Hoffmann-La Roche Ltd. 36
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 36
Celgene Corporation 38
Clinical Trial Overview of Celgene Corporation 38
Pharmacyclics, Inc. 39
Clinical Trial Overview of Pharmacyclics, Inc. 39
Janssen Global Services, LLC 40
Clinical Trial Overview of Janssen Global Services, LLC 40
GlaxoSmithKline plc 41
Clinical Trial Overview of GlaxoSmithKline plc 41
AbbVie Inc. 42
Clinical Trial Overview of AbbVie Inc. 42
Gilead Sciences, Inc. 43
Clinical Trial Overview of Gilead Sciences, Inc. 43
Sanofi 44
Clinical Trial Overview of Sanofi 44
Merck and Co., Inc. 45
Clinical Trial Overview of Merck and Co., Inc. 45
Clinical Trial Overview of Top Institutes / Government 46
National Cancer Institute 46
Clinical Trial Overview of National Cancer Institute 46
Fred Hutchinson Cancer Research Center 48
Clinical Trial Overview of Fred Hutchinson Cancer Research Center 48
The University of Texas M. D. Anderson Cancer Center 49
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 49
Case Comprehensive Cancer Center 50
Clinical Trial Overview of Case Comprehensive Cancer Center 50
Roswell Park Cancer Institute 51
Clinical Trial Overview of Roswell Park Cancer Institute 51
Ohio State University Comprehensive Cancer Center 52
Clinical Trial Overview of Ohio State University Comprehensive Cancer Center 52
Mayo Clinic 53
Clinical Trial Overview of Mayo Clinic 53
Beth Israel Deaconess Medical Center 54
Clinical Trial Overview of Beth Israel Deaconess Medical Center 54
Massachusetts General Hospital 55
Clinical Trial Overview of Massachusetts General Hospital 55
Duke University 56
Clinical Trial Overview of Duke University 56
Five Key Clinical Profiles 57
Appendix 195
Abbreviations 195
Definitions 195
Research Methodology 196
Secondary Research 196
About GlobalData 197
Contact Us 197
Disclaimer 197
Source 198

List of Tables
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Region, 2014* 8
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 9
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 10
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 11
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 12
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, North America, Top Countries, 2014* 13
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 14
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 15
Proportion of Refractory Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials, G7 Countries (%), 2014* 16
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 17
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 18
Proportion of Refractory Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials, E7 Countries (%), 2014* 19
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 20
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Withdrawn Clinical Trials, 2014* 25
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Terminated Clinical Trials, 2014* 26
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 28
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 31
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 32
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 36
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Celgene Corporation, 2014* 38
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Pharmacyclics, Inc., 2014* 39
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Janssen Global Services, LLC, 2014* 40
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 41
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by AbbVie Inc., 2014* 42
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Gilead Sciences, Inc., 2014* 43
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014* 44
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck and Co., Inc., 2014* 45
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 46
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Fred Hutchinson Cancer Research Center, 2014* 48
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014* 49
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Case Comprehensive Cancer Center, 2014* 50
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Roswell Park Cancer Institute, 2014* 51
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Ohio State University Comprehensive Cancer Center, 2014* 52
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Mayo Clinic, 2014* 53
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Beth Israel Deaconess Medical Center, 2014* 54
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Massachusetts General Hospital, 2014* 55
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Duke University, 2014* 56

List of Figures
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Region (%), 2014* 8
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 9
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 10
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 11
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 12
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 13
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 14
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2014* 15
Proportion of Refractory Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials, G7 Countries (%), 2014* 16
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 17
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 18
Proportion of Refractory Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials, E7 Countries (%), 2014* 19
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 20
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 28
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 30
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 32
GlobalData Methodology 196

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Chronic Myelocytic Leukemia (CML) - Market Insights, Epidemiology and Market Forecast-2023

Chronic Myelocytic Leukemia (CML) - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Chronic Myelocytic Leukemia (CML) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the ...

Acute Myeloid Leukemia (AML) - Market Insights, Epidemiology and Market  Forecast-2023

Acute Myeloid Leukemia (AML) - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Acute Myeloid Leukemia (AML) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...

Chronic lymphocytic leukemia- Market Insights, Epidemiology and Market Forecast-2023

Chronic lymphocytic leukemia- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Chronic lymphocytic leukemia - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.